Scopul nostru este sprijinirea şi promovarea cercetării ştiinţifice şi facilitarea comunicării între cercetătorii români din întreaga lume.
Autori: Medioni J, Banu E, Helley D, Scotte F, Fournier L, Mejean A, Chedid A, Azizi M, Andrieu JM, Oudard S.
Editorial: Elsevier, Eur Urol, 55(5), p.January 13, 2009.
We present a case series of seven patients with metastatic renal cell carcinoma treated with bevacizumab (10mg/kg) in combination with sunitinib 25–50mg as salvage therapy after disease progression under sunitinib monotherapy. Two patients had a partial response, four had stable disease, and one patient had disease progression. After a median follow-up of 17.2 mo, median progression-free survival and overall survival were 8.5 and 15.1 mo, respectively. Two patients experienced exacerbation of their preexisting hypertension; there were no grade 4 toxicities. The bevacizumab–sunitinib combination in sunitinib-refractory patients seems active and has a tolerable toxicity profile.
Cuvinte cheie: bevacizumab, cancer renal, tratament de salvare, sunitinib // Bevacizumab, Renal cell carcinoma, Salvage therapy, Sunitinib